Glenmark Pharmaceuticals will remain in focus as the French pharma major Sanofi filed a patent infringement petition against Glenmark for the cardiac drug Multaq, in the district court of Delaware, US. Sanofi and Sanofi-Aventis US LLC filed the suit against Glenmark and Actavis (Watson) on February 26 seeking to prevent the duo from commercialising its product prior to the expiration of certain US patents. Glenamark had filed its application with US FDA for its drug on January 24.

comment COMMENT NOW